Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.45 USD | +3.55% |
|
+5.62% | +3.94% |
06-20 | JMP Securities Adjusts Price Target on Iovance Biotherapeutics to $23 From $25, Maintains Market Outperform Rating | MT |
06-11 | Iovance Biotherapeutics, Inc. Elects Frederick G. Vogt as Director | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.94% | 2.28B | |
-44.08% | 7.74B | |
+8.98% | 3.56B | |
-24.94% | 1.89B | |
-17.38% | 1.75B | |
+4.89% | 939M | |
+21.75% | 751M | |
-11.57% | 674M | |
-30.82% | 485M | |
+4.37% | 304M |
- Stock Market
- Equities
- IOVA Stock
- News Iovance Biotherapeutics, Inc.
- Iovance Biotherapeutics Shares Fall After Q1 Revenue Misses Estimates